Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities

doi:10.3748/wjg.v28.i28.3573

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6913)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

434

WORD

109

HTML

3872

Figures (1-2)

647

Tables (1-3)

369

Sum=5431

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

175

Download

349

Sum=524

Publishing Process of This Article

Item

Count

Browse

363

Download

595

Sum=958

Jul 28, 2022 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jul 28, 2022; 28(28): 3573-3585
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3573

Table 2 Clinical trials approaching combination of systemic treatment and ablation enrolling, recruiting, or waiting for final results

Trial	Trial registration	Drug	Control	n	Disease stage	Local treatment	Expected termination	Primary end-point
CHECKMATE 9DX	NCT03383458	Nivolumab	Placebo	530	Early/intermediate	Surgery/Ablation	2025	Recurrence-free survival
KEYNOTE 937	NCT03867084	Pembrolizumab	Placebo	950	Early/intermediate	Surgery/Ablation	2025	Recurrence-free survival and overall survival
IMBRAVE 050	NCT04102098	Atezolizumab + Bevacizumab	Surveillance	662	Early/intermediate /advanced	Surgery/Ablation	2027	Recurrence-free survival
EMERALD-2	NCT03847428	Durvalumab + Bevacizumab	Placebo	888	Early/intermediate	Surgery/Ablation	2024	Recurrence-free survival

Citation: da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol 2022; 28(28): 3573-3585
URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3573.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i28.3573